ALT Colour coding reflects the overall direction of available evidence and does not account for heterogeneity between trials or differences in effect size. Green dot: currently available trials indicate exclusively or predominantly beneficial effects. Yellow dot: currently available trials indicate varying effects (or results are interpretable in varying ways), where evidence does altogether not indicate clear beneficial or clear adverse effects. Red dot: currently available trials indicate exclusively or predominantly adverse effects. Grey dot: currently available trials have not detected an effect on the outcome. White dot: unknown, currently no trials available.

ALT Cumulative incidence plots showing time from randomisation to occurrence of first primary kidney composite event (A) and narrower secondary kidney composite event (B). Pooled data from the SELECT, FLOW, and SOUL trials, in the full analysis set. The primary kidney composite included onset of persistent ≥50% reduction in eGFR, kidney failure (persistent eGFR <15 mL/min per 1·73 m2 or initiation of kidney replacement therapy), kidney-related death, or cardiovascular-related death. Narrower secondary kidney composite included the above criteria, excluding cardiovascular-related death. eGFR=estimated glomerular filtration rate. HR=hazard ratio. IR=incidence rate (number of events per 100 years of observation).